Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 2
1986 11
1987 9
1988 28
1989 23
1990 25
1991 36
1992 23
1993 36
1994 28
1995 43
1996 25
1997 31
1998 41
1999 46
2000 51
2001 86
2002 127
2003 136
2004 179
2005 244
2006 385
2007 438
2008 496
2009 622
2010 629
2011 713
2012 691
2013 742
2014 711
2015 664
2016 789
2017 957
2018 1040
2019 1168
2020 1052
2021 794
2022 430
2023 240
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

11,913 results

Results by year

Filters applied: . Clear all
Page 1
The safety and side effects of monoclonal antibodies.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. Hansel TT, et al. Nat Rev Drug Discov. 2010 Apr;9(4):325-38. doi: 10.1038/nrd3003. Epub 2010 Mar 22. Nat Rev Drug Discov. 2010. PMID: 20305665 Review.
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.
Tralokinumab-ldrm.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Apr 1;79(8):616-617. doi: 10.1093/ajhp/zxac020. Am J Health Syst Pharm. 2022. PMID: 35267017 No abstract available.
Tremelimumab-actl.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2023 Mar 7;80(6):324-328. doi: 10.1093/ajhp/zxac365. Am J Health Syst Pharm. 2023. PMID: 36645069 No abstract available.
Durvalumab-Associated Hypopituitarism.
Ogbue O, Garisa M, Furqan M, Alqaisi S, Patel R. Ogbue O, et al. Am J Ther. 2023 Nov-Dec 01;30(6):e583-e586. doi: 10.1097/MJT.0000000000001529. Epub 2022 Jun 15. Am J Ther. 2023. PMID: 37921684 No abstract available.
Managing adverse effects of immunotherapy.
Gerson JN, Ramamurthy C, Borghaei H. Gerson JN, et al. Clin Adv Hematol Oncol. 2018 May;16(5):364-374. Clin Adv Hematol Oncol. 2018. PMID: 29851932 Review.
Camrelizumab-Associated Psoriasis.
Hui HZ, Wang YJ, Cheng JR, Mao H, Jiang X, Guo HX, Diao QC, Shi BJ. Hui HZ, et al. Am J Ther. 2023 Sep-Oct 01;30(5):e461-e463. doi: 10.1097/MJT.0000000000001591. Epub 2022 Dec 23. Am J Ther. 2023. PMID: 37713694 No abstract available.
11,913 results
You have reached the last available page of results. Please see the User Guide for more information.